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discounting rate of 3% was used for both costs and health outcomes simulation. 
One-way sensitivity analysis was performed. RESULTS: Therapy conversion to 
IAsp would result in increased life expectancy by 0.81 years per patient (13.93 vs. 
13.12) and QALY by 1.44 QALYs per patient (9.87 vs. 8.43), due to reduced 
incidences of diabetes-related complications. Treatment and management costs 
of diabetes were increased by CNY (Chinese Yuan) 11,690 (48,850 vs. 37,160) and 
1,982 (39,924 vs. 37,942) respectively. However, the costs of complications, 
including cerebrovascular disease, renal complications, ulcer/amputation/ 
neuropathy, eye complications, and hypoglycemia events, were reduced by CNY 
199,028 (102,590 vs. 301,618), resulting in total direct medical cost saving of CNY 
185,357. Sensitivity analyses demonstrated robustness of the results. 
CONCLUSIONS: Switching from HI to IAsp in T2DM patients in China was 
associated with not only improvement of life expectancy and QALYs, but also 
significant reduction in total direct medical costs. Therapy conversion to IAsp 
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OBJECTIVES: To assess the cost-effectiveness (CE) of starting insulin detemir 
(IDet) ± oral glucose-lowering drugs (OADs) in people with type 2 diabetes (T2D) 
in countries in different economic circumstances based on observational data 
gathered in routine clinical practice. METHODS: The A1chieve® study assessed 
safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin 
analog therapy. The CE analyses included people starting IDet in Algeria (n=473), 
India (n=1,491), Mexico (n=101), Indonesia (n=109), South Korea (n=487) and in 
Malaysia based on people in 4 ASEAN countries (n=456). Data were collected on 
clinical effectiveness, adverse events, and patient reported outcomes using the 
EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with country-specific costs for complications and 
therapies and background mortality rates. Incremental cost-effectiveness ratios 
(ICER) are expressed as cost/QALY in local currencies, USD and fractions of local 
GDP per capita based on starting IDet. CE was pre-defined as <3*GDP. RESULTS: 
One-year ICERs were Algeria (DZD 617,658; USD 7,758; GDP 1.48), India (INR 
58,454; USD 1,054; GDP 0.71), Mexico (MXN 62,952; USD 4,835; GDP 0.48), 
Indonesia (IDR 22,920,222; USD 2,381; GDP 0.68), South Korea (KRW 4,273,409; 
USD 3,935; GDP 0.18), Malaysia (MYR 17,613; USD 5,758; GDP 1.34). 30-year ICERs 
were: Algeria (DZD 368,200; USD 4,625; GDP 0.88), India (INR 39,214; USD 707, GDP 
0.48), Mexico (MXN -2,887; USD -222; GDP -0.02); Indonesia (IDR 3,995,329; USD 
415; GDP 0.12), South Korea (KRW 15,139; USD 14, GDP 0.00) and Malaysia (MYR 
10,499; USD 3,432; GDP 0.80). Sensitivity analyses on the 30 year time horizon 
showed the findings to be robust. CONCLUSIONS: Starting IDet in T2D as 
performed in the A1chieve® study was found to be cost-effective across all 
country settings based on a 1 and 30 year time horizon.  
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OBJECTIVES: To assess the cost-effectiveness (CE) of switching from biphasic 
human insulin 30 (BHI 30) ± oral glucose-lowering drugs (OADs) to biphasic 
insulin aspart 30 (BIAsp 30) ± OADs in people with type 2 diabetes (T2D) in 
countries in different economic circumstances based on observational data 
gathered in routine clinical practice. METHODS: The A1chieve® study assessed 
safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin 
analog therapy. The CE analyses included people switching to BIAsp 30 in Saudi 
Arabia (n=401), India (n=866) and Indonesia and Malaysia based on people in 4 
ASEAN countries (n=175). Data were collected on clinical effectiveness, adverse 
events, and outcomes using the EQ-5D questionnaire. CE analyses used the IMS 
CORE diabetes model with 1 and 30 year time horizons, with country-specific 
costs for complications and therapies and background mortality rates. 
Incremental cost-effectiveness ratios (ICERs) are expressed as cost/QALY in local 
currencies, USD and in fractions of local GDP per capita based on switching from 
BHI 30 to BIAsp 30. CE was pre-defined as <3*GDP. RESULTS: One-year ICERs 
were: Saudi Arabia (SAR 12,913; USD 3,443; GDP 0.17), India (INR 36,001; USD 649; 
GDP 0.44), Indonesia (IDR 120,507,714; USD 12,520; GDP 2.92), Malaysia (MYR 
40,321; USD 13,180; GDP 3.08). 30-year ICERs were: Saudi Arabia (SAR 837; USD 
223; 0.03 GDP), India (INR 21,696; USD 391, GDP 0.26), Indonesia (IDR 51,416,633; 
USD 5,342; GDP 1.25), Malaysia (MYR 19,967; USD 5,342; GDP 1.25). Sensitivity 
analyses on the 30 year time horizon showed the findings to be robust. 
CONCLUSIONS: Switching from BHI 30±OADs to BIAsp 30±OADs in T2D as 
performed in the A1chieve® study was found to be cost-effective across all 
country settings at 1 and 30 year time horizons. The Malaysian analyses showed 
borderline cost-effectiveness using 1 year time horizon but cost-effectiveness 
assuming 30 year time horizon.  
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OBJECTIVES: To assess the cost-effectiveness (CE) of switching therapy from 
insulin glargine (IGlar) ± oral glucose-lowering drugs (OADs) to biphasic insulin 
aspart 30 (BIAsp 30) ± OADs in people with type 2 diabetes (T2D) in Saudi Arabia 
and India based on observational data gathered in routine clinical practice. 
METHODS: The A1chieve® study assessed safety and outcomes over 24 weeks in 
66,726 people with T2D starting insulin analog therapy. Most participants (96%) 
stated better glycemic control as reason to switch therapy, 31% also stated 
problems with hypoglycemia as reason of switch. The CE analyses included 
people switching to BIAsp 30 in Saudi Arabia based on people in 7 Gulf countries 
(n=103) and in India (n=191). Data were collected on clinical effectiveness, 
adverse events, and patient reported outcomes using the EQ-5D questionnaire. 
CE analyses used the IMS CORE diabetes model with 1 and 30-year time horizons, 
with country-specific costs for complications and therapies and country-specific 
background mortality rates. Incremental cost-effectiveness ratios (ICERs) are 
expressed as cost/QALY in local currencies, USD and in fractions of local GDP per 
capita based on switching from IGlar to BIAsp 30. CE was pre-defined as <3*GDP. 
RESULTS: For both a 1 and 30 year time horizons the switch was found to be less 
costly and have better outcomes. 1-year ICERs were: Saudi Arabia (SAR -8,958; 
USD -2,388; GDP -0.12) and India (INR -60,194; USD -1,086; GDP -0.73). 30-year 
ICERs were: Saudi Arabia (SAR -14,242; USD -3,798; GDP -0.19) and India (INR  
-55,914; USD -1,008; GDP -0.68). Sensitivity analyses on the 30 year time horizon 
showed the findings to be robust. CONCLUSIONS: Switching therapy from IGlar 
to BIAsp 30 in T2D as performed in the A1chieve® study was found to be 
dominant across both country settings based on a 1 and 30 year time horizon.  
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OBJECTIVES: To assess the cost-effectiveness (CE) of starting biphasic insulin 
aspart 30 (BIAsp 30) therapy ± oral glucose-lowering drugs (OADs) in people with 
type 2 diabetes (T2D) in countries in different economic circumstances based on 
observational data gathered in routine clinical practice. METHODS: The 
A1chieve®study assessed safety and outcomes over 24 weeks in 66,726 people 
with T2D starting insulin analog therapy. The CE analyses included people 
starting BIAsp 30 in Saudi Arabia (n=901), India (n=7,546), Indonesia (n=153), in 
Malaysia based on people in 4 ASEAN countries (n=430) and in Algeria based on 
people in 3 countries in North-West Africa (n=279). Data were collected on 
clinical effectiveness, adverse events, and patient reported outcomes using the 
EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with country-specific costs for complications and 
therapies and background mortality rates. Incremental cost-effectiveness ratios 
(ICER) are expressed as cost/QALY in local currencies, USD and in fractions of 
local GDP per capita based on starting BIAsp 30. CE was pre-defined as <3*GDP. 
RESULTS: 1-year ICERs were: Saudi Arabia (SAR 10,741; USD 2,864; GDP 0.14), 
India (INR 35,182; USD 635; GDP 0.43), Indonesia (IDR 40,487,477; USD 4,207; GDP 
1.2), Malaysia (MYR 13,061; USD 4,270; GDP 1.00), Algeria (DZD 246,422; USD 3,095, 
GDP 0.73). 30-year ICERs were: Saudi Arabia (SAR -3,004; USD -801; GDP -0.04), 
India (INR 20,516; USD 370; GDP 0.25), Indonesia (IDR 15,710,332; USD 1,632; GDP 
0.47), Malaysia (MYR 8,038; USD 2,627; GDP 0.61), Algeria (DZD 155,659; USD 1,955; 
GDP 0.46). Sensitivity analyses on the 30 year time horizon showed the findings 
to be robust. CONCLUSIONS: Starting BIAsp 30 in T2D as performed in the 
A1chieve® study was found to be cost-effective across all country settings based 
on a 1 and 30 year time horizon.  
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OBJECTIVES: To evaluate long-term health economic outcomes of switching 
from human soluble insulin (HI) to insulin aspart (IAsp) on a basal-bolus regimen 
in type 2 diabetes mellitus (T2DM) patients in a Chinese setting. METHODS: The 
previously published and validated IMS Core Diabetes Model was used to project 
long-term life expectancy, quality-adjusted life years (QALY) and total direct 
medical costs. Baseline patient characteristics and treatment effects were based 
on Asian subgroup (n=185, countries including China, Bangladesh, India, 
Pakistan, Indonesia, South Korea, Malaysia, Philippines, Singapore and Taiwan) 
in A1chieve study which is a prospective, multi-centre, open-label, non-
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interventional and 24-week observational study. Treatment costs were derived 
from drug retail prices in Chinese market. Diabetes management and 
complication costs were obtained from Chinese published data. Projections were 
made from a societal perspective for 30 years, with costs and life years 
discounted at 3% annually. One-way sensitivity analysis was performed. 
RESULTS: Switching to IAsp from HI was projected to increase life expectancy by 
0.48 year (14.11 vs. 13.63) and QALY by 0.96 QALY per patient (9.83 vs. 8.87), due 
to reduced incidences of diabetes-related complications. IAsp was associated 
with reduced total direct medical costs by CNY (Chinese Yuan) 108,464 (204,853 
vs. 313,317), due to reduced complication costs by CNY 129,778 (107,084 vs. 
236,862) and increased treatment and management costs of CNY (Chinese Yuan) 
20,128 (57,391 vs. 37,263) and 1,186 (40,378 vs. 39,192) respectively. Sensitivity 
analyses demonstrated robustness of the results. CONCLUSIONS: Switching to 
IAsp from HI for Chinese patients with T2DM on a basal-bolus regimen was not 
only associated with improvements in life expectancy and QALYs, but also 
significant reduction in total direct medical costs. Switching to IAsp from HI on a 
basal-bolus regimen is a cost-saving treatment strategy for T2DM patients in a 
Chinese setting.  
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OBJECTIVES: The Cardiff Type-2 Diabetes Model is a fixed time increment 
stochastic simulation model written in Microsoft Excel and C++; initially 
developed in 2003, it has been used to support a number of cost-effectiveness 
and public health policy decisions. The model is fundamentally built around the 
risk equations reported from the United Kingdom Prospective Diabetes Study 
(UKPDS) and concerns persist regarding the validity of these equations in 
contemporary populations. Therefore, the objective of this study was to validate 
the model’s output to recently published outcomes trials to establish if the 
UKPDS equations remain credible. METHODS: Simulated cohorts reflecting the 
baseline characteristics associated with key outcomes studies (ASPEN, 
ADVANCE, ACCORD, VADT, ADDITION, ASCOT, CARDS and long term follow-up 
of UKPDS) were generated and treatment effects applied to reflect intensive 
versus conventional arms. Predicted and observed events, over a time horizon 
consistent with each trial, were compared and goodness of fit determined, using 
the coefficient of determination (R2). RESULTS: Across all validation studies 
predicted versus observed events resulted in an R2 statistic of 0.90. This result 
was obtained when including data from UKPDS, for which the model gave an 
exceptionally fit (R2 = 0.95) When excluding UKPDS the overall R2 = 0.7. Despite 
the less accurate fit, there was a consistent trend demonstrated from the model 
although a noteworthy lack of fit was observed for the ACCORD blood pressure 
trial (non-fatal myocardial infarctions [MI]) and ACCORD glucose lowering trial 
(non- fatal MI and congestive heart failure) in which the predicted events rates 
by the model were substantially lower than reported in the trials. Similarly, for 
the ADVANCE trial, non-fatal strokes were significantly under-predicted by the 
model. CONCLUSIONS: This study suggests the UKPDS risk equations within 
type-2 diabetes models remain credible for supporting contemporary technology 
assessment and health policy decisions.  
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OBJECTIVES: Long-acting insulin analogues are currently not reimbursed  
in diabetes type-2 in Poland. The population who could benefit most from its 
reimbursement are patients whose glycaemic control cannot be maintained 
using protamine Hagedorn insulin (NPH). The aim of the analysis was to assess 
cost-effectiveness of insulin glargine (IGlar) as compared to NPH in treatment  
of such subpopulation. METHODS: Cost-utility analysis in lifetime horizon was 
conducted using widely validated CORE Diabetes Model. This is a commonly 
used Markov model which simulates the progression of physiological parameters 
and incidence of diabetes-related complications over time. The analysis  
was based on systematic literature review of clinical trials. Due to lack of data 
from RCTs for the subpopulation defined as lack of NPH efficacy, the data source 
were non-randomized clinical trials. These are so far the best available evidence. 
Based on the identified studies two comparisons were made: IGlar versus NPH, 
both in combination with oral antidiabetic drugs (OAD) or with OAD / bolus 
insulin. The following efficacy parameters were taken into account: change  
in HbA1c, BMI, hypoglycemia rate. Costs were estimated from public payer’s 
(National Health Fund, NHF), and NHF+patients’ perspective. Costs, quality-
adjusted life years (QALYs) and incremental cost-utility ratios (ICURs)  
were estimated as a result of modeling. Annual discount rates of 5% and 3.5% 
were applied on costs and health effects, respectively. The acceptability 
threshold was set at 25,800 EUR/QALY. RESULTS: The difference in QALY was 
0.792 for IGlar+OAD vs NPH+OAD and 0.695 for IGlar+OAD/bolus versus 
NPH+OAD/bolus. From NHF+patients’ perspective the difference in costs was 
1592 EUR and 1355 EUR, respectively. ICURs were 2010 EUR and 1950 EUR, 
respectively. Results from NHF perspective were similar – ICURs did not exceed 
2000 EUR. CONCLUSIONS: In Polish setting insulin glargine is highly cost-
effective in patients in whom NPH insulin does not provide adequate glycaemic 
control.  
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OBJECTIVES: Type-2 diabetes mellitus (T2DM) is a complex chronic disease; 
consequently, T2DM cost-effectiveness models are invariably complex. Despite 
efforts to validate these models and promote transparency it is often unclear to 
decision makers how these models map input settings to output results and 
which factors are most influential. Therefore, the objective of this study was to 
assess the relative impact of three key components of diabetes therapy on cost-
effectiveness: changes in HbA1c, hypoglycemia and body mass index (BMI). 
METHODS: This study utilized the IMS CORE diabetes model (CDM) to model four 
profiles associated with managing type 2 diabetes; Treatment 1: -0.5% HbA1c; 
Treatment 2: -0.5% HbA1c and BMI -1 Kg/m2; Treatment 3: -0.5% HbA1c, BMI -1 
Kg/m2 and 2 non-severe hypoglycemia (NSHE) avoided; Control: no effect. 
Lifetime analyses were conducted using NHANES to populate the patient 
characteristics in the modeling. Disutilities of -0.0052 and -0.0038 were applied to 
each NSHE and 1 unit increase in BMI respectively. Discounting was applied at 
3% and US 2010 costs were used. RESULTS: Compared to Control (no effect), 
Treatments 1, 2 and 3 were associated with discounted gains in lifetime quality 
adjusted life expectancy (QALE) of 0.059, 0.119 and 0.241 respectively (0.091, 0.185 
and 0.354 undiscounted). Each unit decrease in NSHE and BMI were associated 
with similar gains in QALE associated with a 0.5% HbA1c reduction. 
CONCLUSIONS: Within models of T2DM, the health utility gains associated with 
weight reduction and avoidance of NSHE are applied to all patients in a 
treatment arm; this is in contrast to changes in HbA1c that only impacts the 
probability of a future event (cardiovascular and/or micro-vascular). 
Consequently, therapies associated with the avoidance of weight gain and 
hypoglycaemia will likely exhibit favourable cost-effectiveness profiles 
compared to improvements in glycaemic control only.  
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OBJECTIVES: Accurate estimation of baseline cardiovascular (CV) risk and 
relative risk reduction (RRR) is crucial to ensure that economic evaluations of 
new health technologies for the treatment of type 2 diabetes (T2DM) are robust. 
Many economic models (such as the CORE Diabetes Model) use risk equations 
(RE) derived from UKPDS and concerns persist regarding their validity; 
particularly as new equations are published. The objective of this study was to 
compare the consistency of predicted CV risk using RE derived from various 
T2DM populations. METHODS: All CV equations identified from a recent 
systematic review, derived from populations with T2DM, were coded and 
validated. Equations from Australia (Fremantle), New Zealand (DCS), Sweden 
(Cederholm), China (Yang), Scotland (DARTS), USA (ARIC) and UK (UKPDS) were 
included. Predicted 5-year CV risk was obtained using baseline cohort 
characteristics taken from ACCORD. Relative risk reductions (RRR) were obtained 
by applying a 10% relative reduction in HbA1c, total cholesterol and SBP both 
individually and in combination. RESULTS: Mean 5-year predicted risk of CVD 
was 11.0% (SE 1.9%); minimum of 3.4% (ARIC) and maximum 20.7% (DARTS). A 
10% reduction in HbA1c, TC and SBP resulted in a mean RRR of 6.4%(SE 0.7%), 
6.8% (SE 1.5%)and 9.8% (SE 2.3%) respectively. The DCS equation (New Zealand) 
predicted the lowest RRR for HbA1c, TC and SBP reduction (4.3%, 1.0% and 3.5% 
respectively). The highest RRR for HbA1c change was Cederholm (8.3%) and the 
DARTS equation for TC and SBP, 10.3% and 18.9%, respectively. CONCLUSIONS: 
The difference in absolute risk across these equations does not appear 
dependent on geographical location or study recruitment period. Generally, the 
UKPDS equations produced consistent absolute CV risk and RRR estimates close 
to the group averages; this is of reassurance given their widespread use. Health 
care policy decisions that rely on CV risk estimation should perform sensitivity 
analysis across multiple equations where practicable.  
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OBJECTIVES: There is a substantial body of epidemiological evidence relating 
body-mass index (BMI) to increased risk of mortality in subjects with type-2 
diabetes mellitus (T2DM). Cardiovascular (CV) and mortality risk equations 
typically incorporate the effects of elevated BMI via the inter-relationship 
between modifiable CV risk factors (cholesterol and systolic blood pressure) and 
BMI; this approach may underestimate true mortality risk. Therefore, the 
objective of this study was to assess by how much existing risk equations 
underestimate the risk of mortality as a function of increasing levels of BMI. 
METHODS: We projected life expectancy (LE) using the IMS CORE Diabetes Model 
(CDM), a validated and widely used simulation model designed to predict the 
health care costs and benefits associated with diabetes. Projected LE was 
obtained using patient level data (PLD) for subjects with T2DM from NHANES. CV 
and mortality risk was assessed using UKPDS risk equations and additional BMI 
cause specific mortality included via results from published prospective analyses 
